Introduction:This is a prospective study aiming to describe how cervical cancer and its treatment can affect the sexuality of a specific population of Moroccan women survivors of this disease.Materiels and Methods:It is a comparison of clinical features and Female Sexual Function Index (FSFI) of 3 balanced groups of women, made up of 100 survivors of cervical cancer, 100 survivors of non-gynecological cancer and a group of 100 healthy women.Results:97% of the patients stopped their full sexual activity at the time of treatment; the time interval between treatment and regular sexual activity was 8 months for the cervical cancer group, and 5.8 months for non-gynecologic cancer (P =0.001). Vaginal length assessed by pelvic examination during follow up visits was estimated at about 6.2 cm, 9.2 cm and 9.5 cm respectively for the cervical cancer group, non-gynecologic cancer group and the control group (p=0.04). On the basis of the FSFI questionnaire, the analysis of the 6 main sexuality parameter scores did attest worse results for the variables related to sexual function for cervical cancer group, but not in a statistically significant way.Conclusion:In order to preserve an optimal quality of life after cervical cancer, the sexual dimension is a crucial parameter to take into consideration throughout treatment phases, especially radiation (by encouraging sexual intercourses, and using vaginal dilators during the treatment). Moroccan survivors of this disease must be treated according to a multidisciplinary approach, that includs the psychological component.
Le cancer de la vulve est une affection néoplasique rare, représentant moins de 5% des cancers génitaux de la femme. L'objectif de ce travail est de décrire le profil épidémiologique, clinique, paraclinique, thérapeutique et évolutif du cancer de la vulve chez la population de la région de l'Oriental du Maroc, ceci à travers une analyse rétrospective de toutes les patientes suivies pour un cancer de la vulve, de juin 2007 à janvier 2014, et traitées au sein de l'hôpital d'Oncologie du Centre Hospitalier Universitaire Mohamed VI de Oujda au Maroc. Notre analyse rétrospective a porté sur 34 patientes, d'une médiane d'âge de 65,7 ans, dont 52,9% étaient des multipares. Le motif de consultation dominant était le prurit dans 94.1% des cas. La moyenne du délai de consultation était de 16 mois, allant de 2 mois à 8 ans. L'ignorance et la pudeur ont été les causes majeures de ce retard diagnostique, puisque 73.5% des patientes avaient déjà une maladie localement avancée au diagnostic. Le traitement chirurgical a été proposé à 61.4% des cas, il a consisté en une vulvectomie radicale avec un curage inguinal bilatéral dans 68.5% des cas. Le recours à la radiothérapie adjuvante a été indiqué chez 41.2% des cas, 5.9% des patientes ont bénéficié d'une radiothérapie néo adjuvante, et 20,6% d'une radiothérapie exclusive associée à une chimiothérapie concomitante. La chimiothérapie palliative a été proposée pour 8.8% des patientes. Le taux de survie globale à 3 ans est à 65%, le taux de récidives locorégionales ou à distance est de 17.3% des cas. Les particularités culturelles et sociales des patientes de la région de l'Oriental du Maroc, qui sont suivies pour un cancer de la vulve, sont des facteurs influençant le traitement et ses résultats. Des efforts de prévention et de sensibilisation supplémentaires sont à mener afin de réduire l'incidence des stades localement avancés, et de permettre un traitement curatif à cette population.
Urachal carcinomas is a rare and aggressive tumor, accounting for less than 1% of all bladder cancers. We report a case of a 32-year-old man, with no past medical history, complaining of a total hematuria. The abdominal computed tomography scan revealed an exophytic mass of 3 cm on the dome of the bladder, extending to the urachus. The computed tomography scan of chest, abdomen and pelvis did not show neither regional or distant metastasis. Partial Cystectomy with umbilectomy was performed. Histopathology was in favor of urachal adenocarcinoma, classed pT3a, based on Sheldon's staging system, pT2b based on Mayo system, and pT2 based on Ontario system.
Background: Intensity Modulated Radiation Therapy (IMRT) is currently employed as a major arm of treatment in multiforme glioblastoma (GBM). The present study aimed to compare 3D-CRT with IMRT to assess tumor volume coverage and OAR sparing for the treatment of malignant gliomas. Materials and methods: We assessed 22 anonymized patients datasets with High Grade Glioblastoma who had undergone post-operative Intensity Modulated Radiotherapy (IMRT) and 3D Conformal Radiotherapy (3D-CRT), This study will compare and contrast treatment plans Rapidarc and 3D-CRT to determine which technology improves significantly dosimetric parameters. Results: Plans will be assessed by reviewing the coverage of the PTV using mean, maximum and minimum doses while the OAR doses will be compared using the maximal doses for each, as set out in the QUANTEC dose limits. Conclusion: The use of IMRT seems a superior technique as compared to 3D-CRT for the treatment of malignant gliomas having the potential to increase the dose to the PTV while sparing OARs optimally.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.